ARIAD Pharmaceuticals (ARIA) : During the past 4 weeks, traders have been relatively bearish on ARIAD Pharmaceuticals (ARIA), hence the stock is down -9.16% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.46% relative to the S&P 500. The 4-week change in the price of the stock is -5.19% and the stock has fallen -5.06% in the past 1 week. The stock has recorded a 20-day Moving Average of 2.89% and the 50-Day Moving Average is 7.82%.
ARIAD Pharmaceuticals (NASDAQ:ARIA): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.05 and $7.04 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.26. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.13, notching a gain of 1.42% for the day. The total traded volume was 2,989,094 . The stock had closed at $7.03 on the previous day.
The company Insiders own 8.2% of ARIAD Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -4.02% . Institutional Investors own 70.69% of ARIAD Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -24.37%. In a related news, The Securities and Exchange Commission has divulged that Clackson Timothy P, officer (President, R&D, CSO) of Ariad Pharmaceuticals Inc, had unloaded 61,422 shares at an average price of $7.48 in a transaction dated on July 1, 2016. The total value of the transaction was worth $459,437.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).